<DOC>
	<DOCNO>NCT00769327</DOCNO>
	<brief_summary>RATIONALE : Nilotinib imatinib mesylate may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase II trial study well give nilotinib together imatinib mesylate work treat patient early chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Nilotinib Imatinib Mesylate Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess complete cytogenetic response rate 12 month patient Philadelphia chromosome- BCR-ABL-positive early chronic phase chronic myelogenous leukemia treat nilotinib imatinib mesylate . Secondary - To assess complete cytogenetic response rate 6 24 month patient . - To assess major complete molecular response rate 6 , 12 , 24 month patient . - To assess frequency type BCR-ABL kinase domain mutation 24 month 3 year study treatment . - To assess rate failure time failure 12 , 24 , 60 month patient . - To assess compliance , toxicity , adverse event patient . - To understand relationship response , gene expression profile , biomarkers , drug plasma concentration patient . OUTLINE : This multicenter study . Patients receive oral nilotinib twice daily month 1-3 , 7-9 , 13-15 , 19-21 oral imatinib mesylate daily month 4-6 , 10-12 , 16-18 , 22-24 . Treatment continue 24 month absence disease progression unacceptable toxicity . Patients may eligible continue oral nilotinib oral imatinib mesylate another 36 month interest patient . Blood sample bone marrow biopsy collect periodically cytogenetic response chromosome banding analysis FISH analysis ; real-time quantitative PCR mutational analysis single nucleotide polymorphism analysis BCR-ABL transcript ; gene expression profile correlative biomarker study . After completion study therapy , patient follow every 6 month 3 year every 12 month 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically cytogenetically confirm chronic myelogenous leukemia meeting follow criterion : Early chronic phase disease ( &lt; 6 month diagnosis ) Philadelphia chromosomepositive disease BCRABLpositive PATIENT CHARACTERISTICS : WHO performance status 01 ALT AST = 2.5 time upper limit normal ( ULN ) ( 5.0 time ULN consider due leukemia ) Alkaline phosphatase = 2.5 time ULN ( unless consider due leukemia ) Serum bilirubin = 1.5 time ULN Serum creatinine = 1.5 time ULN Serum amylase = 1.5 time ULN Serum lipase = 1.5 time ULN Normal serum level follow correctable supplement : Potassium Total calcium ( correct serum albumin ) Magnesium Phosphorus Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier method contraception study 3 month follow completion study treatment No impaired cardiac function , include follow : LVEF &lt; 45 % MUGA scan echocardiogram Uncontrolled congestive heart failure Uncontrolled hypertension Uncontrolled angina pectoris Myocardial infarction within past 12 month No significant electric heart abnormality , include follow : History active ventricular atrial tachyarrhythmias Congenital long QT syndrome and/or QTc &gt; 450 msec screen ECG No history acute ( within one year ) chronic pancreatitis No impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) No acute chronic liver renal disease consider unrelated leukemia No know diagnosis HIV infection No concurrent severe and/or uncontrolled medical condition ( e.g. , uncontrolled diabetes , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol No primary malignancy currently clinically significant require active intervention PRIOR CONCURRENT THERAPY : More 2 week since prior major surgery recover More 30 day since prior imatinib mesylate , washout period â‰¥ 7 day More 4 week since prior investigational drug No prior hematopoietic stem cell transplantation No concurrent therapeutic coumarin derivates ( i.e. , warfarin , acenocoumarol , phenprocoumon ) No concurrent medication would prolong QT interval No concurrent chemotherapy , investigational agent , radiotherapy , biologic therapy Prior treatment hydroxyurea anagrelide allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>